Trial Profile
One-year Efficacy of Adjunctive Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients with Glaucoma Inadequately Controlled under Maximum Medical Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Feb 2017
Price :
$35
*
At a glance
- Drugs Ripasudil (Primary)
- Indications Glaucoma
- Focus Therapeutic Use
- 22 Feb 2017 New trial record